Skip to Content

'
Dejka M. (Steinert) Araujo, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
P.O. Box 301402, Unit 450
Unit Number: 450
Houston, TX 77230-1402

Education & Training

Degree-Granting Education

1999 University of Arkansas for Medical Sciences, Little Rock, AR, MD, Medical Sciences
1995 Notre Dame, Notre Dame, IN, BA, Theology

Postgraduate Training

2002-2005 Clinical Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
2000-2002 Clinical Residency, University of Alabama, Birmingham, AL
1999-2000 Clinical Internship, University of Alabama, Birmingham, AL

Board Certifications

11/2007 Medical Oncology

Experience/Service

Academic Appointments

Fellowship Program Director, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2011-present
Associate Faculty Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 10/2009-present
Quality Officer, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2009-present
Assistant Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2005-8/2011

Institutional Committee Activities

Member, Clinical Competency Committee of the Hematology/Oncology Fellowship Program, 7/2013-present
Member, Graduate Medical Education Institutional Review Subcommittee, 3/2012-present
Sarcoma Medical Oncology Representative, M.D. Anderson Cancer Center Fellowship Executive Committee, 4/2006-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of Pazopanib and Vorinostat: a Therapeutic Approach for Inhibiting Mutant p53-Mediated Angiogenesis and Facilitating Mutant p53 Degradation. Annals of Oncology 26(5):1012-8, 5/2015.
2. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 120(16):2448-56, 8/2014. e-Pub 5/2014. PMID: 24797726.
3. Bednarski BK, Araujo DM, Yi M, Torres KE, Lazar A, Trent JC, Cormier JN, Pisters PW, Lev DC, Pollock RE, Feig BW, Hunt KK. Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors. Ann Surg Oncol 21(8):2499-505, 8/2014. e-Pub 3/18/2014. PMCID: PMC4524653.
4. Conter HJ, Gopalakrishnan V, Ravi V, Ater JL, Patel S, Araujo DM. Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience. Sarcoma 2014:375151, 2014. e-Pub 6/2014. PMCID: PMC4082947.
5. Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, Ross JS, Stephens PJ, Palmer GA, Ali SM. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol 14(7(1)):8, 2014. e-Pub 1/14/2014. PMCID: PMC3896681.
6. Dumont SN, Araujo DM, Munsell MF, Salganick JA, Dumont AG, Raymond KA, Linassier C, Patel S, Benjamin RS, Trent JC. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med 2(4):553-63, 8/2013. e-Pub 7/2013. PMCID: PMC3799290.
7. Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clinical Sarcoma Research, 5/2013. e-Pub 5/2013.
8. Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: Results of a phase 2 trial (SARC 005). Cancer 119(8):1555-61, 4/2013. e-Pub 1/2013. PMID: 23335221.
9. Demicco EG, Park MS, Araujo DM, Fox PS, Bassett RL, Pollock RE, Lazar AJ, Wang WL. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Modern Pathology 25(9):1298-306, 9/2012.
10. Katz D, Boonsirikamchai P, Choi H, Lazar AJ, Wang WW, Xiao L, Park MS, Ravi V, Benjamin RS, Araujo DM. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clinical Sarcoma Research 2(1):2, 1/2012.
11. Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, Lòpez-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJ. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. Clin Sarcoma Res 2(1):25, 2012. e-Pub 12/2012. PMCID: PMC3599544.
12. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer, 11/2011. PMID: 21480200.
13. Yang J, Yang D, Sun Y, Sun B, Wang G, Trent J, Araujo D, Chen K, Zhang W. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 117(21):4925-38, 11/2011.
14. Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after defininitive treatment of cutaneous angiosarcoma of the face and scalp. Head Neck 33(5):661-7, 5/2011.
15. Shinder R, Jackson TL, Araujo D, Prieto VG, Guadagnolo BA, Esmaeli B. Preoperative Radiation Therapy in the Management of Recurrent Orbital Hemangiopericytoma. Ophthal Plast Reconstr Surg, 1/2011. PMID: 21242853.
16. Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig J, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients with Cancer. Annals of Internal Medicine 153(6):358-367, 9/2010.
17. Jonathan C. Trent, MD, PhD, Shalin S. Patel, Jianhu Zhang, PhD, Dejka Araujo, MD, Juan-Carlos Plana, MD, Daniel J. Lenihan, MD, Dominic Fan, PhD, Shreyaskumar R. Patel, MD, Robert S. Benjamin, MD, and Aarif Y. Khakoo, MD. Rare Incidence of Congestive Heart Failure in Gastrointestinal Stromal Tumor and Other Sarcoma Patients Receiving Imatinib Mesylate. Cancer 116(1):184-192, 1/2010. PMID: 19885836.
18. Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ, Fan D, Patel SR, Benjamin RS, Khakoo AY. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 116:184-192, 2010.
19. Wang WL, Mayordomo E, Czerniak BA, Abruzzo LV, Cin PD, Araujo DM, Lev DC, López-Terrada D, Lazar AJ. Fluorescence in situ hybridization is a useful ancillary diagnostic tool for extraskeletal myxoid chondrosarcoma. Mod Pathol 21(11):1303-10, 11/2008. PMID: 18587326.
20. Shome D, Trent J, Espandar L, Hatef E, Araujo DM, Song CD, Kim SK, Esmaeli B. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. Ophthalmology 115(3):483-7, 3/2008. PMID: 18201764.
21. McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res 13(22 Pt 1):6727-34, 11/2007. PMID: 18006774.
22. Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J, Patel SR, Benjamin RS, Raymond AK. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 107(9):2237-44, 11/2006. PMID: 16998931.
23. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 106(7):1617-23, 4/2006. PMID: 16518826.
24. Steinert DM, McAuliffe JC, Trent JC. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother 6(1):105-13, 1/2005. PMID: 15709888.
25. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 12(1):44-56, 1/2005. PMID: 15668652.

Invited Articles

1. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR Pathway in Angiosarcoma, Epithelioid Hemangioendothelioma, and Hemangiopericytoma/Solitary Fibrous Tumor. Current Opinion in Oncology 22(4):351-355, 7/2010.
2. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Current Opinion in Oncology 21(4):327-31, 7/2009. PMID: 19444101.
3. Steinert DM, Patel SR. Recent studies in novel therapy for metastatic sarcomas. Hematol Oncol Clin North Am 19(3):573-90, viii, 6/2005. PMID: 15939198.
4. Steinert DM, Blakely LJ, Salganick J, Trent JC. Molecular targets in therapy for human soft-tissue and bone sarcomas. Curr Oncol Rep 5(4):295-303, 7/2003. PMID: 12781071.

Abstracts

1. Raut CP, Espat J, Maki RG, Araujo DM, Keir CH, Williams TF, DeMatteo RP,. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis. J Clin Oncol 33(suppl; abstr 10537), 2015.
2. Conley AP, Satcher RL, Wang WL, Lazar AJ, Fox PS, Lin PP Moon B, Bird JE, Araujo DM, Ravi V, Somaiah N, Patel S, Benjamin RS, Lewis VO. Clinical characteristics and treatment outcomes of clear cell chondrosarcoma: MD Anderson Cancer Center Series. J Clin Oncol 33(suppl;abstr 10531), 2015.
3. Vadhan-Raj S, Ravi V, Zhou X, Araujo DM, Somaiah N, Conley AP, Daniel M, Benjamin RS, Patel S, Spasojevic I. Effects of fosaprepitan (FOS) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen of doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study. J Clin Oncol 33(suppl; abstr e20714), 2015.
4. Somaiah N, Gomes DBD, Madewell JE, Wang WL, Conley AP, Ravi V, Araujo DM, Ludwig JA, Benjamin RS, Patel S. Defining the chemotherapy (CT) response in well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) of the retroperitoneum (RP): A tertiary referral cancer center experience. J Clin Oncol 32(5s):suppl; abstr 10583, 2014.
5. Subbiah V, Agarwal R, Filip J, Tsimberidou AM, Patel S, Benjamin RS, Ludwig JA, Anderson PM, Araujo DM, Ravi V, Conley AP, Somaiah N, Wang WL, Naing A, Zinner R, Hong DS, Meric-Bernstam F. Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision in medicine. J Clin Oncol 32(5s):suppl; abstr 10595, 2014.
6. Vadhan-Raj S, Zhou X, Araujo DM, Somaiah N, Conley AP, Ravi V, Daniel M, Benjamin RS, Patel S. Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosfamide (AI): Randomized cross-over study 32(5s):suppl; abstr 9616, 2014.
7. Gupta R, Ramesh N, Rose EJ, Carter K, Araujo DM, Benjamin RS, Patel S, Nates JL, Ravi V. Survival and outcomes of critically ill sarcoma patients admitted to the intensive care unit. J Clin Oncol 32(5s):suppl; abstr 10576, 2014.
8. Williams LA, Araujo DM, Quiling S, Ali NN, Ahaneku H, Jing K, Trent JC, Cleeland CS. Symptoms in gastrointestinal stromal tumors. J Clin Oncol 32(5s):suppl; abstr 9637, 2014.
9. Abouharb S, Warneke CL, Ravi V, Ludwig JA, Lazar AJF, Patel S, Benjamin RS, Araujo DM. Synovial sarcoma: Evaluation of response to treatment with gemcitabine and docetaxel. J Clin Oncol 32(5s):suppl; abstr 10564, 2014.
10. Ravi V, Ramesh N, Patnana M, Conley AP, Somaiah N, Zarzour MA, Ingram D, Little L, Protopopov A, Lazar AJF, Araujo DM, Torres KE, Patel S, Zhang J, Ali SM, Miller VA, Stephens PJ, Benjamin RS, Hwu P, Futreal A. Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications. J Clin Oncol 32(5s):suppl; abstr 10512, 2014.
11. Hensley ML, Wathen K, Maki RG, Araujo DM, Sutton GP, Priebat DA, George S, Baker LH. 3-year follow-up of SARC005: Adjuvant treatment og high risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D). CTOS(Poster #78):38, 10/2011.
12. Trent JC, Salganick JA, Thall PF, Patel SR, Araujo DM, Benjamin RS. Efficacy and safety of low-dose protracted irinotecan in patients with advanced sarcomas: results from a phase II study. CTOS - Oral Presentation:90, 10/2011.
13. Demicco E, Park M, Araujo D, Bassett R, Lazar AJ, Wang WL,. Solitary fibrous tumor/hemangiopericytoma: clinicopathologic predictors of outcome. CTOS(Poster # 205):55, 10/2011.
14. Dumont SN, Trent JC, Patel S, Araujo DM, Dumont AG, Benjamin RS. A phase II study of low-dose protracted irinotecan in patients with advanced sarcomas. ASCO (#10064), 6/2011.
15. Gao J, McAuliffe JC, Lazar AJF, Wang W, Choi H, Hunt K, Araujo DM, Pollock RE, Benjamin RS, Trent JC. Mechanism of early radiographic response to imatinib in GIST. ASCO (#10049), 6/2011.
16. Park MS, Patel S, Ravi V, Conley AP, Trent JC, Lazar AJF, Lev D, Wang X, Benjamin RS, Araujo DM. The role of chemotherapy in advanced hemangiopericyoma/solitary fibrous tumor. ASCO (#10097), 6/2011.
17. Ravi V, Yang J, Araujo DM, Park MS, Benjamin RS, Zhang W, Trent JC, Patel S. The role of E-cadherin expression in response and outcome in patients with leiomyosarcoma treated with chemotherapy. ASCO (#10096), 6/2011.

Book Chapters

1. Steinert DM, Trent JC:. Gastrointestinal stromal tumors. In: Ajani JA, Curley SA, Janjan NA, Lynch PM Gastrointestinal Cancer. 3, M.D. Anderson Cancer Care Series. Ed(s) Buzdar AU, Freedman RS. Springer Science + Business Media, Inc: New York, 2005.

Last updated: 3/7/2016